|
|
Endocrine/Metabolic
|
|
Antidiabetic agent
|
|
To improve glycemic control in type 2 diabetes
|
|
1. Adults: Give by SC inj in abdomen, thigh, or upper arm once daily. Initially 0.6mg/day for 1 week, then 1.2mg/day; may increase to 1.8mg/day. If >3 days elapsed since last dose, reinitiate at 0.6mg/day, then titrate. 2. Children: <18yrs: not recommended.
|
|
Category C
|
|
Headache, GI upset, antibody formation, immunogenicity reactions (eg, urticaria), constipation; rare: pancreatitis (discontinue if occurs), papillary thyroid carcinoma, anaphylactic reactions and angioedema (discontinue if occurs).
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
|
|
|
If you want your friend to read or know about this article, Click here
|
|
|